{"id":"NCT04123561","sponsor":"Taiwan Liposome Company","briefTitle":"Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo- and Active-controlled Study to Evaluate the Efficacy and Safety of TLC599 in Patients With Osteoarthritis of the Knee","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-26","primaryCompletion":"2022-02-03","completion":"2022-02-03","firstPosted":"2019-10-11","resultsPosted":"2024-10-08","lastUpdate":"2024-10-08"},"enrollment":504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis of the Knee"],"interventions":[{"type":"DRUG","name":"TLC599","otherNames":["TLC599 Injection"]},{"type":"DRUG","name":"DSP","otherNames":["Dexamethasone Sodium Phosphate"]},{"type":"OTHER","name":"Normal Saline","otherNames":[]}],"arms":[{"label":"TLC599","type":"EXPERIMENTAL"},{"label":"Dexamethasone sodium phosphate","type":"ACTIVE_COMPARATOR"},{"label":"Normal Saline","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3 randomized, double-blind, placebo- and active comparator-controlled study of TLC599.","primaryOutcome":{"measure":"Change From Baseline in WOMAC Pain at Week 12 for TLC599 12 mg Versus Placebo","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"TLC599 12mg","deltaMin":-0.968,"sd":null},{"arm":"Placebo","deltaMin":-0.798,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0372"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":46,"countries":["United States","Australia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":252},"commonTop":["Arthralgia","Back pain","Hypertension","COVID-19","Urinary tract infection"]}}